InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,316.51
(
-0.09%
)
US TECH 100
18,266.00
(
0.19%
)
Dow Jones
39,794.64
(
-0.20%
)
Brent Oil
81.85
(
-0.73%
)
Bitcoin
70,471.92
(
0.49%
)
Post# of 251894
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 162066

Tuesday, 06/04/2013 4:04:37 AM

Tuesday, June 04, 2013 4:04:37 AM

Post# of 251894

Quiz (low difficulty): Why did SNY take a writeoff for the failure of Iniparib (#msg-88593358) but not for the failure of Otamixaban (#msg-88592744)?

Because Sanofi got Iniparib through the 2009 purchase of BiPar Sciences Inc., while Otamixaban was discovered and developed in-house.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up